Surveillance in Barrett's oesophagus: A need for reassessment?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 10, 1998, Pages 990-996

  Nandurkar, Sanjay ^a   Talley, Nicholas J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEPEAN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; CANCER RISK; CANCER SCREENING; DISEASE ASSOCIATION; ESOPHAGUS CARCINOMA; HUMAN; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT;

EID: 0031769071     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00559.x     Document Type: Review

References (67)

1. Dent J, Bremner CG, Collen MJ, Haggitt RC, Spechler SJ. Barrett's oesophagus. Working party report to the World Congress of Gastroenterology, Sydney, 1990. J. Gastroenterol. Hepatol. 1991; 6: 1-22.
2. Stein J. Oesophageal cancer: Screening and surveillance. Dis. Esoph. 1996; 9 (Suppl. 1): 3-19.
3. Cameron AJ. Barrett's esophagus: Does the incidence of adenocarcinoma matter? Am. J. Gastroenterol. 1997; 92: 193-4.
4. Kahrilas PJ. It's not the American way - yet. Am. J. Gastroenterol. 1994; 89: 657-8.
5. Spechler SJ. Endoscopic surveillance for patients with Barrett's esophagus: does the cancer risk justify the practice? Ann. Intern. Med. 1987; 106: 902-4.
6. van der Burgh A, Dees J, Hop WCJ, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5-8.
7. Streitz JM, Andrews CW, Ellis FH. Endoscopic surveillance in Barrett's. Does it help? J. Thorac. Cardiovasc. Surg. 1993; 105: 383-8.
8. Achkar E, Carey W. Cost of surveillance for adenocarcinoma in Barrett's esophagus. Am. J. Gastroenterol. 1988; 83: 291-4.
9. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of Barrett's esophagus. Am. J. Gastroenterol. 1994; 89: 670-80.
10. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastrooesophageal junction. Lancet 1994; 344: 1533-6.
11. Nandurkar S, Talley NJ, Martin CJ, Ng THK, Adams S. Short segment Barrett's oesophagus: Prevalence, diagnosis and associations. Gut 1997; 40: 710-15.
12. Weston AP, Krmpotich P, Makdisi WF et al. Short segment Barrett's esophagus: Clinical and histological features associated endoscopie findings, and association with gastric intestinal metaplasia. Am. J. Gastroenterol. 1996; 91: 981-6.
13. Johnston MH, Hammond AS, Laskin W, Jones DM. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal oesophagus on routine endoscopy. Am. J. Gastroenterol. 1996; 91: 1507-11.
14. Schnell T, Sontag SJ, Chejfec G. Adenocarcinomas arising in tongues or short segments of Barrett's esophagus. Dig. Dis. Sci. 1992; 37: 137-43.
15. Nishimaki T, Watanabe K, Suzuki T, Hatakeyama K, Watanabe H. Early esophageal adenocarcinoma arising in a short segment of Barrett's mucosa after total gastrectomy. Am. J. Gastroenterol. 1996; 9: 1856-7.
16. Axon ATR. Cancer surveillance in ulcerative colitis: A time for reappraisal. Gut 1994; 35: 587-9.
17. Gyde S. Screening for colorectal cancer in ulcerative colitis: Dubious benefits and high costs. Gut 1990; 31: 1089-97.
18. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in hereditary nonpolyposis colorectal cancer (HNPCC) families. Gastroenterology 1995; 108: 1405-11.
19. Colorectal screening guidelines: Clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642.
20. Haggitt RC. Barrett's esophagus, dysplasia and adenocarcinoma. Hum. Pathol. 1994; 25: 982-93.
21. Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: Standardised classification with provisional clinical implications. Hum. Pathol. 1983; 14: 931-68.
22. Reid BJ, Barrett MT, Galipeau PC, Sanchez CA, Neshat K, Cowan DS. Barrett's esophagus: Ordering the events that lead to cancer. Eur .J. Cancer Prev. 1996; 5 (Suppl. 2): 57-65.
23. Reid BJ Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: Cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993; 105: 119-29.
24. Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR. Barrett's oesophagus. Comparison of benign and malignant cases. Ann. Surg. 1983; 198: 554-65.
25. McArdle JE, Lewin KJ, Randall G, Weinstein W. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum. Pathol. 1992; 23: 479-82.
26. Hamilton SR, Smith RRL. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am. J. Clin. Pathol. 1987; 87: 301-12.
27. van der Veen AH, Dees J, Blankensteijn JD, Blankenstein MA. Adenocarcinoma in Barrett's esophagus: An overrated risk. Gut 1989; 30: 14-18.
28. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32: 1441-6.
29. Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 1989;96: 1249-56.
30. Daly JM, Karnell LH, Menck HR. National cancer data base report on esophageal carcinoma. Cancer 1996; 78: 1820-8.
31. Menke-Pluymers MBE, Schoute NW, Mulder AH, Hop WCJ, van Blankenstein M, Tilanus HW. Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus. Gut 1992; 33: 1454-8.
32. Sugimachi K, Ohno S, Matsuda H, Mori M, Matsuoka H, Kuwano H. Clinicopathologic study of early stage esophageal carcinoma. Br. J. Surg. 1989; 76: 759-63.
33. Wright TA, Gray MR, Morris AI et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996; 39: 574-9.
34. Blot WJ, Devasa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-9.
35. Blot WJ, Devasa SS, Fraumeni JF. Continuing climb in rates of esophageal adenocarcinoma: An update. JAMA 1993; 270: 1320 (letter).
36. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-13.
37. Thomas RJS, Lade S, Giles GG, Thursfield V. Incidence trends in oesophageal and proximal gastric carcinoma in Victoria. Aust. NZ J. Surg. 1996; 66: 271-5.
38. Armstrong RW, Borman B. Trends in incidence rates of adenocarcinoma of the esophagus and gastric cardia in New Zealand, 1978-92. Int. J. Epidemiol. 1996; 25: 941-7
39. Hesketh PJ, Clapp RW, Doos WG, Spechler SJ. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989; 64: 526-30.
40. New South Wales Central Cancer Registry. Cancer Council Report. Sydney: Cancer Council 1989.
41. Spechler SJ, Robbins AH, Rubins HB et al. Adenocarcinoma and Barrett's esophagus: An overrated risk? Gastroenterology 1984; 87: 927-33.
42. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N. Engl. J. Med. 1985; 313: 857-9.
43. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br. J. Surg. 1988; 75: 760-3.
44. Ovaska J, Miettinen M, Kivilaasko E. Adenocarcinoma arising in Barrett's esophagus. Dig. Dis. Sci. 1989; 34: 1336-9.
45. Watson RGP, Porter KG, Sloan JM. Incidence of adenocarcinoma in Barrett's esophagus and an evaluation of endoscopie surveillance. Eur. J. Gastroenterol. Hepatol. 1991; 3: 159-62.
46. Williamson WA, Ellis FH, Gibb P et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch. Intern. Med. 1991; 151: 2212-16.
47. Drewitz DJ, Sampliner RE, Garewal HS.The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed for 4.8 years. Am. J. Gastroenterol. 1997; 92: 212-15.
48. Ferraris R, Luigina B, Conio M et al. Incidence of Barrett's adenocarcinoma in an Italian population: An endoscopie surveillance programme. Eur. J. Gastroenterol. Hepatol. 1997; 9: 881-5.
49. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918-22.
50. Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high-grade dysplasia in Barrett's esophagus. Am. J. Gasrroenterol. 1993; 88: 1832-6.
51. Levine DS. Management of dysplasia in columnar-lined esophagus. Gastroenterol. Clin. North Am. 1997; 26: 613-33.
52. Wright TA. High grade dysplasia in Barrett's oesophagus. Br. J. Surg. 1997; 84: 760-6.
53. Edwards MJ, Gable DR, Lentsch AB, Richardson JD. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high grade dysplasia. Ann. Surg. 1996; 223: 585-91.
54. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high grade dysplasia. An indication for prophylactic esophagectomy. Ann. Surg. 1996; 224: 66-71.
55. Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC. Barrett's esophagus with high grade dysplasia: An indication for esophagectomy? Ann. Thorac. Surg. 1992; 54: 199-204.
56. Reid BJ, Haggitt RC, Rubin CE et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum. Pathol. 1988; 19: 166-78.
57. Schnell T, Sontag G, Chejfec G et al. High grade dysplasia (HGD) is not an indication for surgery in patients with Barrett's esophagus. Gastroenterology 1996; 110: A590.
58. Levine DC, Haggitt RC, Irvine S et al. Natural history of high grade dysplasia in Barrett's esophagus. Gastroenterology 1996; 110: A550.
59. O'Rourke I, Tait N, Bull C, Gebski V, Holland M, Johnson DC. Oesophageal cancer: Outcome of modern surgical management. Aust. NZ J. Surg. 1995; 65: 11-65.
60. Adam DJ, Craig SR, Sang CTM, Cameron EWJ, Walker WS. Esophagectomy for carcinoma in the octogenarian. Ann. Thorac. Surg. 1996; 61: 190-4.
61. Sampliner RE, Jaffe P. Malignant degeneration of Barrett's esophagus: The role of laser ablation and photodynamic therapy. Dis. Esophagus 1995; 8: 104-8.
62. Overholt BF, Panjehpour M. Barrett's esophagus: Photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa and treatment of superficial esophageal cancer. Gastroentest. Endosc. 1995; 42: 64-70.
63. Carter R, Glasziou P, van Oortmarssen G et al. Cost effectiveness of mammographie screening in Australia. Aust. J. Public Health 1993; 17: 42-50.
64. Salkeld G, Young G, Irwig L, Haas M, Glasziou P. Cost effectiveness analysis of screening by fecal occult blood testing for colorectal cancer in Australia. Aust. NZ J. Public Health 1996; 20: 138-43.
65. Australian Health Ministers' Advisory Council. Cervical Cancer Screening Evaluation Committee. Cervical cancer screening in Australia: Options for change. Australian Institute of Health Prevention Program Evaluation series No. 2. Canberra: Australian Government Publishing Service, 1991.
66. Smart CR. Limitations of the randomized trial for the early detection of cancer. Clinical perspective. Cancer 1997; 79: 1740-6.
67. Richter JE, Falk GW. Barrett's esophagus and adenocarcinoma. The need for a consensus conference. J. Clin. Gastroenterol. 1996; 23: 88-90.